A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

View Full Paper

Ask AI

Bookmark

Abstract

Saroglitazar appeared to be an effective and safe therapeutic option for improving hypertriglyceridemia in patients with T2DM.

No takes yet. Share an insight, caveat, or question.

Jani et al. (2013) studied this question.

View Full Paper

Ask AI

Bookmark